Maria Isabel Manley and Marina Barnden report on the worrying implications for the innovative pharmaceutical industry of the European Court of Justice ruling in ABPI v MHRA.
It comes as a shock to the innovative pharmaceutical industry that, following the European Court of Justice’s 22 April ruling in Association of the British Pharmaceutical Industry v Medicines and Healthcare products Regulatory Agency1-4, public bodies forming part of a national health service are entitled to offer financial inducements to doctors to prescribe cheaper medicinal products...
Please login to read the full article.
